Analysis of naïve Patients With Age-related Macular Degeneration of the Neovascular Type and Treated With Aflibercept (Eylea®) in "Treat-and-extend" at CHU Brugmann

Age-related Macular Degeneration Clinical Trial

Official title:

Retrospective Analysis of naïve Patients With Age-related Macular Degeneration of the Neovascular Type and Treated With Aflibercept (Eylea®) in "Treat-and-extend" at CHU Brugmann

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04891835
• Other study ID #: CHUB-CHRAIBI-KAADOUD
• Status: Completed
• Start date: April 13, 2021
• Est. completion date: September 22, 2021

Study information

• Verified date: March 2022
• Source: Brugmann University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Age-related macular degeneration (AMD) is a leading cause of blindness in people over 50. Neovascular AMD, the most serious and severe form, is characterized by the appearance, spread and growth of subretinal new vessels. One of the major molecular mediators is vascular endothelial growth factor (VEGF).

Intra-vitreous (IVI) injection of an anti-VEGF can slow the progression of neovascular AMD and stabilize vision in the majority of cases. Aflibercept (Eylea®) is one of the anti-VEGF molecules approved in Belgium to treat neovascular AMD.

At the start of its use, aflibercept was first injected monthly and then according to the PRN "reactive" protocol (Pro Renata). Over time, a new treatment strategy has emerged: the "treat-and-extend" (T&E). This is individualized patient care, the objective of which is to reduce the frequency of injections while ensuring inactivity of the disease. This begins with the loading dose, i.e. 3 injections given 4 weeks apart. Thereafter, the interval is lengthened in increments of 1 or 2 weeks provided that the visual and anatomical results remain stable. In the event of deterioration, the interval is shortened while keeping a minimum of 4 weeks between each IVI.

The efficacy and safety of aflibercept, when used in a proactive T&E regimen, was demonstrated in the randomized controlled trial, ALTAIR. However, data on T&E used in practice is still lacking. routine, and particularly the number of injections and treatment intervals over a minimum 24 month treatment period.

The aim of this retrospective study carried out at the CHU Brugmann is to determine the number of injections and the intervals necessary to have encouraging results in terms of visual acuity, over a treatment period of at least one year.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: September 22, 2021
• Est. primary completion date: September 22, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Patients> 50 years old diagnosed with neovascular age related macular degeneration,

• Patients who have never received anti-VEGF treatment,

• Patients who started intra-vitreous injections of aflibercept between 01 January 2014 and November 30, 2019,

• Treatment by "treat-and-extend" directly after the loading dose of aflibercept,

• Availability of the medical file reporting treatment with aflibercept.

Exclusion Criteria:

• Participation in an interventional clinical study during treatment with aflibercept,

• Patients with ocular pathologies who required surgery during the first 24 months of treatment with aflibercept (eg advanced glaucoma or cataracts).

Related Conditions & MeSH terms

• Age-related Macular Degeneration
• Macular Degeneration

Intervention

Other:
• Data extraction from medical files
Data extraction from medical files

Locations

Country	Name	City	State
Belgium	CHU Brugmann	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Laurence Postelmans

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Injections number (first 24 months of treatment)	Number of injections during the first 24 months of treatment	first 24 months of treatment
Primary	Injections interval	Last injection interval during the 2nd year of treatment, in weeks	during the 2nd year of treatment
Secondary	Injection number (up to 4 years of treatment)	Number of injections during the 1st, 2nd, 3rd and 4th year of treatment	up to 4 years of treatment
Secondary	Injections interval (up to 4 years of treatment)	Last injection interval during the 1st, 2nd, 3rd and 4th year of treatment (if applicable), in weeks	up to 4 years of treatment
Secondary	Most stable injection interval	Most stable injection interval during the 2nd, 3rd and 4th year of treatment (if applicable), in weeks	up to 4 years of treatment
Secondary	Overall extension interval	Expected overall extension interval: by 1 week, 2 weeks, 3 weeks or 4 weeks	up to 4 years of treatment
Secondary	Covid 19 impact	Covid19 impact on the injection interval (visits cancelled due to lock-down, shortening/increase of the injection interval due to hospital internal emergency procedures)	up to 4 years of treatment
Secondary	Number of follow-up visits	Number of follow-up visits during each year of treatment up to 4 years	up to 4 years of treatment
Secondary	Visual acuity	Visual acuity at baseline, after 90 days and at the end of each year of treatment up to 4 years	up to 4 years of treatment
Secondary	Age	Age of the patient at baseline	Baseline
Secondary	Eye lesion type	Eye lesion type	Baseline
Secondary	Fluid	Presence or absence of intra-retinal fluid, subretinal fluid, detachment of the pigment epithelium at baseline, after 90 days and at the end of each year of treatment up to 4 years	up to 4 years of treatment
Secondary	Date of first symptoms	Date of first symptoms of neovascular AMD	Baseline
Secondary	Date of first injection	Date of first ranibizumab injection	Baseline
Secondary	Retinal thickness	Retinal thickness at baseline, after 90 days and at the end of each year of treatment up to 4 years	up to 4 years of treatment
Secondary	Treatment regimen	Has there been a change in treatment regimen after the first 12 months of treatment?	first 12 months of treatment
Secondary	Number of patients stopping treatment (12-24 months)	Number of patients stopping treatment between 12 and 24 months of treatment	between 12 and 24 months of treatment
Secondary	Reason for stopping treatment (12-24 months)	Reason for stopping treatment between 12 and 24 months of treatment	between 12 and 24 months of treatment
Secondary	Number of patients stopping treatment (24-36 months)	Number of patients stopping treatment between 24 and 36 months of treatment	between 24 and 36 months of treatment
Secondary	Reason for stopping treatment (24-36 months)	Reason for stopping treatment between 24 and 36 months of treatment	between 24 and 36 months of treatment
Secondary	Number of patients stopping treatment (36-48 months)	Number of patients stopping treatment between 36 and 48 months of treatment	between 36 and 48 months of treatment
Secondary	Reason for stopping treatment (36-48 months)	Reason for stopping treatment between 36 and 48 months of treatment	between 36 and 48 months of treatment
Secondary	Number of patients stopping treatment (first 12 months)	Number of patients who stopped treatment in the first 12 months	first 12 months of treatment
Secondary	Reason for stopping treatment (first 12 months)	Reason for stopping treatment in the first 12 months	first 12 months of treatment